» Articles » PMID: 7819202

Involvement of Glutamate 268 in the Active Site of Human Liver Mitochondrial (class 2) Aldehyde Dehydrogenase As Probed by Site-directed Mutagenesis

Overview
Journal Biochemistry
Specialty Biochemistry
Date 1995 Jan 10
PMID 7819202
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

On the basis of chemical modification studies, it was postulated that glutamate 268 was a component of the active site of liver aldehyde dehydrogenase [Abriola, D. P., Fields, R., MacKerell, A. D., Jr., & Pietruszko, R. (1987) Biochemistry 26, 5679-5684]. To study its role, the residue in human liver mitochondrial (class 2) aldehyde dehydrogenase was mutated to an aspartate, a glutamine, or a lysine, and the enzyme was expressed in Escherichia coli. The mutations did not affect the Km values for NAD or propionaldehyde, but grossly affected the catalytic activity of the enzymes when compared to recombinantly expressed native enzyme; the mutant enzymes had less that 0.4% of the specific activity of the recombinantly expressed native aldehyde dehydrogenase. The mutations also caused a long lag phase to occur prior to the steady state phase of the reaction. The activity of the mutant enzymes could not be restored by the addition of general bases such as sodium acetate, sodium formate, or imidazole. The Kd for NADH was essentially identical for the E268Q mutant and native enzyme. The three mutant forms of the enzyme possessed less than 0.8% of the esterolytic activity of the recombinantly expressed native enzyme. Pre-steady state analysis showed that there was no burst of NADH formation in the dehydrogenase reaction or of p-nitrophenol formation in the esterase reaction. This can be interpreted as implying that glutamate 268 may function as a general base necessary for the initial activation of the essential cysteine residue (302), rather than being involved in only the deacylation or hydride transfer step.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Structural and biochemical evidence that ATP inhibits the cancer biomarker human aldehyde dehydrogenase 1A3.

Castellvi A, Pequerul R, Barracco V, Juanhuix J, Pares X, Farres J Commun Biol. 2022; 5(1):354.

PMID: 35418200 PMC: 9007972. DOI: 10.1038/s42003-022-03311-1.


Retinaldehyde Dehydrogenase Inhibition-Related Adverse Outcome Pathway: Potential Risk of Retinoic Acid Synthesis Inhibition during Embryogenesis.

Cho K, Lee S, Heo J, Kwon Y, Chung D, Yu W Toxins (Basel). 2021; 13(11).

PMID: 34822523 PMC: 8623920. DOI: 10.3390/toxins13110739.


Fragrance in Roxb. Despite the Presence of a Betaine Aldehyde Dehydrogenase 2.

Bhatt V, Barvkar V, Furtado A, Henry R, Nadaf A Int J Mol Sci. 2021; 22(13).

PMID: 34203477 PMC: 8269274. DOI: 10.3390/ijms22136968.


Role of potassium levels in pkBADH heterogeneity of NAD binding site.

Munoz-Bacasehua C, Rosas-Rodriguez J, Arvizu-Flores A, Valenzuela-Soto E J Bioenerg Biomembr. 2020; 52(2):61-70.

PMID: 32128683 DOI: 10.1007/s10863-020-09827-7.


ALDH7A1 inhibits the intracellular transport pathways during hypoxia and starvation to promote cellular energy homeostasis.

Yang J, Hsu J, Park S, Lee S, Li J, Bai M Nat Commun. 2019; 10(1):4068.

PMID: 31492851 PMC: 6731274. DOI: 10.1038/s41467-019-11932-0.